The transition to decentralised clinical trials (DCTs) is expected to generate several benefits for the pharmaceutical and healthcare industry.
GlobalData conducted a survey on different organisations associated with the industry to identify the biggest perceived benefits of DCTs for future users.
Go deeper with GlobalData
Perceived Benefits of Decentralised Trials for Future Users by Company Role
An assessment of the survey results showed that a quarter of government/ academic institute respondents believed that the move would lead to greater participation by patients. Around 21% of clinical/ investigator sites, 17% of other contract service providers, 17% of Pharma/ Biotech and 15% of CROs shared a similar opinion.
Approximately 21% of clinical/ investigator sites opined that DCTs will lead to increased participation by sites. The percentage stands at 19% for CROs, 17% for other contract service providers, 14% for Pharma/ Biotech and 8% for government/ academic institutes.
Around 17% of other contract service providers opined that the transition would allow clinical trials to run during the pandemic. It was followed by Pharma/ Biotech (15%), CROs (13%) and government/ academic institutes (8%).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSeparately, around 25% of other contract providers stated that improved access to suitable trial patients will be the biggest benefit of DCTs. The figure stands at 15% for CROs, 14% for clinical/ investigator sites and 8% for Pharma/ Biotech.
Approximately 25% of government/ academic institutes noted that transitioning to DCTs will allow different study designs rely more on real world data and higher data volume from devices than fixed investigator visit primary endpoints. It is followed by clinical/ investigator sites (21%), Pharma/ Biotech (12%), and CROs (6%) and other contract providers (6%).
Government/ academic institute group also leads in the opinion that that DCTs will improve data quality due to near time data collection and automation as well as reduce trial costs.
Around 10% of CROs, 8% of Pharma/ Biotech, 7% of clinical/ investigator sites and 6% other contract service providers also opined that the transition would reduce trial costs.
Some respondents also expect that it will reduce trial timeline, complexity in running studies at sites and technical complexity in using study related systems.
The analysis is based on responses received for the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.
